Nuvectra Corporation (NASDAQ:NVTR) is a medical device company founded in 2008 that went public in March 2016. NVTR’s flagship product, Algovita, is a neurostimulator that is FDA approved for the treatment of chronic pain of the trunk (human torso) and limbs (reimbursable under existing Medicare codes). Algovita competes with like neurostimulation technologies from Boston Scientific (BSX), Abbott Labs (ABT), Medtronic (MDT) and Nevro Corp. (NVRO). Per NVTR's most recent investor presentation, Algovita produces roughly 20% more stimulation than its peers (its primary competitive advantage).